AstraZeneca’s COVID-19 vaccine may receive EUA from India soon

By Nikita Chaurasia  | Date: 2020-12-24

AstraZeneca’s COVID-19 vaccine may receive EUA from India soon

Reportedly, India intends to grant emergency use authorization (EUA) to Oxford/AstraZeneca’s coronavirus vaccine by next week, following submission of some additional data to the concerned authorities by a few local manufacturers. India could be the first country to approve AstraZeneca’s vaccine as the British drugmaker continues the process of examining data from its clinical trials.

Being the biggest vaccine-making country worldwide, India intends to begin immunizing the population starting next month and is in talks of approving EUA applications for Coronavirus vaccines made by local company Bharat Biotech as well as the American pharmaceutical giant Pfizer Inc., claimed trusted sources.

In this context, experts cite that the AstraZeneca-Oxford COVID-19 shot is essential in countries with lower-income and hot climatic conditions as it is inexpensive, easy to transport, and can be stored at normal fridge temperatures for long periods.

The Central Drugs Standard Control Organization (CDSCO) of India had initially assessed the three applications on 9th December and requested more information from all the pharmaceutical firms, including Serum Institute of India (SII), the company which is reportedly producing the AstraZeneca vaccines.

Although Serum Institute has provided all the data required, the authorities are reportedly awaiting information from Pfizer, and some additional information from Bharat Biotech, sources confirmed.

According to the data released by AstraZeneca of their late-stage trials in Brazil and in the U.K., the vaccine showed 62% efficacy among trial participants who were given two dosages each, and 90% efficacy for a smaller group of people given first a half, and then a full dosage, which evidently forms the base of the anticipated approval.

If sources are to be believed, only two full-dose regimens of the COVID-19 vaccine are being considered by the Indian regulator despite its lower success rate.

India is yet to sign a vaccine supply agreement with any pharmaceutical company; however, Serum Institute has reportedly stockpiled over 50 million doses of the AstraZeneca vaccines and intends to make a total of 400 million doses by July 2021, cited sources knowledgeable with the matter.

Source Credits –

https://in.reuters.com/article/uk-health-coronavirus-india-vaccine-excl/exclusive-india-likely-to-approve-astrazeneca-vaccine-by-next-week-sources-idINKBN28W27I

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...